Itochu stock slips 0.98 percent as AI drug alliance lands

Published on 10/07/2026 at 10:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Itochu stock gains a healthcare angle after the company signed a capital alliance with MOLCURE on October 7, 2026. Fiscal-year net profit reached JPY 900.3 billion.

Itochu, JP3143600009, Illustration mit AI erstellt.

Itochu (ISIN JP3143600009) was last at JPY 2,161.50 on the Tokyo Stock Exchange on October 7, 2026, down JPY 21.50 or 0.98 percent from the prior close. The company announced a capital alliance with MOLCURE on the same date, expanding its exposure to AI-driven drug discovery.

AI alliance broadens healthcare strategy

According to ITOCHU Corporation on October 7, 2026, the agreement gives Itochu a minority equity position in MOLCURE, whose platform uses artificial intelligence, proprietary large language model technology, physical simulations and laboratory data to design and optimize antibody and peptide candidates.

The stated goal is an integrated support system for pharmaceutical and biotechnology companies. Itochu plans to combine MOLCURE's discovery technology with the development-support functions of its wholly owned subsidiary A2 Healthcare and its domestic and international business network.

Cash generation supports the expansion

The healthcare move adds a growth initiative to a business that reported substantial financial resources for the fiscal year ended March 2026. ITOCHU Corporation lists consolidated net profit of JPY 900.3 billion, core operating cash flows of JPY 940 billion and return on equity of 15 percent.

The comparison matters for investors assessing whether new investments are supported by operating performance: core operating cash flows were JPY 940 billion against net profit of JPY 900.3 billion for the same fiscal year. The company also reports total assets of JPY 16.7 trillion and total shareholder equity of JPY 6.6 trillion as of March 2026.

Stock stays below yearly high

At JPY 2,161.50, Itochu stock stood 9.90 percent below its 52-week high of JPY 2,399 and 30.66 percent above its 52-week low of JPY 1,653.60 on October 7, 2026. The session range was JPY 2,161.50 to JPY 2,198.50, with volume of 11,901,600 shares.

The market capitalization was JPY 15.1 trillion on October 7, 2026. The next scheduled checkpoint is the fiscal year 2026 second-quarter results announcement, which ITOCHU Corporation lists for November 4, 2026, at 1:00 p.m. JST.

What matters for Itochu stock

The October 7 alliance is strategically small in disclosed transaction detail but broader in intended scope: it links early-stage AI molecule design with preclinical and clinical development support. For Itochu stock, the November results date will provide the next company-specific test of earnings, cash generation and investment execution.

Itochu stock was last at JPY 2,161.50 on the Tokyo Stock Exchange on October 7, 2026, with a market capitalization of JPY 15.1 trillion and a 52-week range of JPY 1,653.60 to JPY 2,399.